Veröffentlichungsdatum: 25 Juni 2020
Projektträger – zwischengeschaltetes Finanzinstitut
EVAXION BIOTECH A/S
The project will finance the development of a platform for drug discovery exploiting Artificial Intelligence (AI) and the pipeline of potential vaccines and treatments targeting infectious diseases.
The aim is to support the R&D investments that are required in order to further advance the promoter's product pipeline and bring the products to market.
- Dienstleistungen - Erbringung von Freiberuflichen, Wissenschaftlichen und Technischen Dienstleistungen
Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)
EUR 20 million
Gesamtkosten (voraussichtlicher Betrag)
EUR 45 million
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector project. Further details will be assessed during the project due diligence.
Unterzeichnet - 6/08/2020
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).